The FDA Office of Acquisitions and Grants Services supports the Food and Drug Administration’s mission to protect public health by advancing regulatory science and ensuring the safety, efficacy, and quality of medical products, foods, and tobacco. Its core priorities center on accelerating innovatio...
The FDA Office of Acquisitions and Grants Services supports the Food and Drug Administration’s mission to protect public health by advancing regulatory science and ensuring the safety, efficacy, and quality of medical products, foods, and tobacco. Its core priorities center on accelerating innovation in regulatory decision-making through advanced research, digital infrastructure, and analytical capabilities. Key initiatives include the development of digital twins for manufacturing processes, high-throughput toxicology platforms, and computational tools to evaluate complex product safety profiles. The agency actively invests in cutting-edge biotechnology R&D, laboratory instrumentation, and data-driven regulatory science to modernize its scientific evaluation frameworks and enhance evidence-based policymaking.
Procurement patterns reveal a strong emphasis on specialized scientific and technical services, particularly in analytical laboratory instrumentation, biotechnology research, and computational services supporting regulatory workflows. The agency frequently utilizes Broad Agency Announcements (BAAs) to fund long-term, high-risk research collaborations and combines contracting vehicles to integrate software platforms, cloud infrastructure, and specialized data systems. Custom programming, facilities management, and testing services are regularly procured to sustain the technical backbone of its scientific operations.
The agency primarily targets vendors in analytical instrument manufacturing, biotechnology R&D, and professional scientific consulting services. It demonstrates a clear preference for Small Business Administration (SBA) set-asides, with frequent use of SBA and 8(a) programs to foster innovation from small and emerging firms. Vendor relationships are built around technical expertise in regulatory science, laboratory validation, and digital health platforms, with a focus on partners capable of delivering secure, scalable, and compliant solutions for high-stakes public health applications.
Organized under the Department of Health and Human Services, the FDA Office of Acquisitions and Grants Services operates as the central procurement arm for the Food and Drug Administration, supporting its nationwide regulatory mission. It leverages a mix of BAAs, indefinite-delivery/indefinite-quantity (IDIQ) contracts, and sole-source agreements to acquire mission-critical scientific and technical capabilities across diverse domains, ensuring alignment with federal acquisition regulations and public health imperatives.